Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2C19and Proton Pump Inhibitor Dosing

被引：173

作者：

Lima, John J. ^{[1
]}

Thomas, Cameron D. ^{[2
,3
]}

Barbarino, Julia ^{[4
]}

Desta, Zeruesenay ^{[5
]}

Van Driest, Sara L. ^{[6
,7
]}

El Rouby, Nihal ^{[2
,3
,8
]}

Johnson, Julie A. ^{[2
,3
]}

Cavallari, Larisa H. ^{[2
,3
]}

Shakhnovich, Valentina ^{[9
,10
,11
]}

Thacker, David L. ^{[12
,13
]}

Scott, Stuart A. ^{[14
,15
]}

Schwab, Matthias ^{[16
,17
,18
]}

Uppugunduri, Chakradhara Rao S. ^{[19
,20
]}

Formea, Christine M. ^{[21
]}

Franciosi, James P. ^{[22
,23
]}

Sangkuhl, Katrin ^{[4
]}

Gaedigk, Andrea ^{[9
]}

Klein, Teri E. ^{[4
]}

Gammal, Roseann S. ^{[24
,25
]}

Furuta, Takahisa ^{[26
]}

机构：

[1] Nemours Childrens Hlth, Ctr Pharmacogen & Translat Res, Jacksonville, FL USA

[2] Univ Florida, Dept Pharmacotherapy & Translat Res, Coll Pharm, Gainesville, FL USA

[3] Univ Florida, Ctr Pharmacogen & Precis Med, Coll Pharm, Gainesville, FL USA

[4] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[5] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN USA

[6] Vanderbilt Univ, Dept Pediat, 221 Kirkland Hall, Nashville, TN 37235 USA

[7] Vanderbilt Univ, Dept Med, 221 Kirkland Hall, Nashville, TN 37235 USA

[8] Univ Cincinnati, Div Pharm Practice & Adm Sci, James Winkle Coll Pharm, Cincinnati, OH USA

[9] Univ Missouri Kansas City, Div Clin Pharmacol Toxicol & Therapeut Innovat, Sch Med, Kansas City, MO USA

[10] Childrens Mercy Kansas City, Div Gastroenterol Hepatol & Nutr, Kansas City, MO USA

[11] Ctr Childrens Hlth Lifestyles & Nutr, Kansas City, MO USA

[12] Indiana Univ Sch Med, Dept Clin Pharmacol, Indianapolis, IN 46202 USA

[13] Translat Software, Bellevue, WA USA

[14] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA

[15] Sema4, Stamford, CT USA

[16] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[17] Univ Hosp, Dept Clin Pharmacol, Tubingen, Germany

[18] Univ Tubingen, Dept Pharm & Biochem, Tubingen, Germany

[19] Univ Geneva, Fac Med, Dept Pediat Gynecol & Obstet, CANSEARCH Res Lab, Geneva, Switzerland

[20] Geneva Univ Hosp, Oncol Hematol Unit, Dept Pediat Gynecol & Obstet, Geneva, Switzerland

[21] InterMt Healthcare, Dept Pharm Serv & Intermt Precis Genom, Salt Lake City, UT USA

[22] Nemours Childrens Hosp, Div Gastroenterol Hepatol & Nutr, Orlando, FL USA

[23] Univ Cent Florida, Dept Pediat, Coll Med, Orlando, FL USA

[24] MCPHS Univ, Dept Pharm Practice, Sch Pharm, Boston, MA USA

[25] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN USA

[26] Hamamatsu Univ Sch Med, Ctr Clin Res, Hamamatsu, Shizuoka, Japan

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷 / 06期

基金：

美国国家卫生研究院; 欧盟地平线“2020”;

关键词：

SINGLE-DOSE PHARMACOKINETICS; HELICOBACTER-PYLORI; POOR METABOLIZERS; INTRAGASTRIC PH; GENE VARIANT; 20; MG; CYP2C19; OMEPRAZOLE; PANTOPRAZOLE; POLYMORPHISMS;

D O I：

10.1002/cpt.2015

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Proton pump inhibitors (PPIs) are widely used for acid suppression in the treatment and prevention of many conditions, including gastroesophageal reflux disease, gastric and duodenal ulcers, erosive esophagitis,Helicobacter pyloriinfection, and pathological hypersecretory conditions. Most PPIs are metabolized primarily by cytochrome P450 2C19 (CYP2C19) into inactive metabolites, andCYP2C19genotype has been linked to PPI exposure, efficacy, and adverse effects. We summarize the evidence from the literature and provide therapeutic recommendations for PPI prescribing based onCYP2C19genotype (updates at ). The potential benefits of usingCYP2C19genotype data to guide PPI therapy include (i) identifying patients with genotypes predictive of lower plasma exposure and prescribing them a higher dose that will increase the likelihood of efficacy, and (ii) identifying patients on chronic therapy with genotypes predictive of higher plasma exposure and prescribing them a decreased dose to minimize the risk of toxicity that is associated with long-term PPI use, particularly at higher plasma concentrations.

引用

页码：1417 / 1423

页数：7

共 50 条

[21] Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update
Relling, Mary, V
Schwab, Matthias
Whirl-Carrillo, Michelle
Suarez-Kurtz, Guilherme
Pui, Ching-Hon
Stein, Charles M.
Moyer, Ann M.
Evans, William E.
Klein, Teri E.
Guillermo Antillon-Klussmann, Federico
Caudle, Kelly E.
Kato, Motohiro
Yeoh, Allen E. J.
Schmiegelow, Kjeld
Yang, Jun J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (05) : 1095 - 1105
[22] Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
Johnson, J. A.
Gong, L.
Whirl-Carrillo, M.
Gage, B. F.
Scott, S. A.
Stein, C. M.
Anderson, J. L.
Kimmel, S. E.
Lee, M. T. M.
Pirmohamed, M.
Wadelius, M.
Klein, T. E.
Altman, R. B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (04) : 625 - 629
[23] Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing
Caudle, K. E.
Rettie, A. E.
Whirl-Carrillo, M.
Smith, L. H.
Mintzer, S.
Lee, M. T. M.
Klein, T. E.
Callaghan, J. T.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (05) : 542 - 548
[24] Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy
Robinson, Katherine M.
Eum, Seenae
Desta, Zeruesenay
Tyndale, Rachel F.
Gaedigk, Andrea
Crist, Richard C.
Haidar, Cyrine E.
Myers, Alan L.
Samer, Caroline F.
Somogyi, Andrew A.
Zubiaur, Pablo
Iwuchukwu, Otito F.
Whirl-Carrillo, Michelle
Klein, Teri E.
Caudle, Kelly E.
Donnelly, Roseann S.
Kharasch, Evan D.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (04) : 932 - 938
[25] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes
Gonsalves, Stephen G.
Dirksen, Robert T.
Sangkuhl, Katrin
Pulk, Rebecca
Alvarellos, Maria
Vo, Teresa
Hikino, Keiko
Roden, Dan
Klein, Teri E.
Poler, S. Mark
Patel, Sephalie
Caudle, Kelly E.
Gordon, Ronald
Brandom, Barbara
Biesecker, Leslie G.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (06) : 1338 - 1344
[26] Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Scott, S. A.
Sangkuhl, K.
Stein, C. M.
Hulot, J-S
Mega, J. L.
Roden, D. M.
Klein, T. E.
Sabatine, M. S.
Johnson, J. A.
Shuldiner, A. R.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) : 317 - 323
[27] Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
Scott, S. A.
Sangkuhl, K.
Gardner, E. E.
Stein, C. M.
Hulot, J-S
Johnson, J. A.
Roden, D. M.
Klein, T. E.
Shuldiner, A. R.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (02) : 328 - 332
[28] Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
El Rouby, Nihal
Lima, John J.
Johnson, Julie A.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (04) : 447 - 460
[29] Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori
Furuta, T
Shirai, N
Ohashi, K
Ishizaki, T
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (02): : 131 - 143
[30] Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy
Duarte, Julio D.
Thomas, Cameron D.
Lee, Craig R.
Huddart, Rachel
Agundez, Jose A. G.
Baye, Jordan F.
Gaedigk, Andrea
Klein, Teri E.
Lanfear, David E.
Monte, Andrew A.
Nagy, Mohamed
Schwab, Matthias
Stein, C. Michael
Uppugunduri, Chakradhara Rao S.
van Schaik, Ron H. N.
Donnelly, Roseann S.
Caudle, Kelly E.
Luzum, Jasmine A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (04) : 939 - 947

← 1 2 3 4 5 →